DGAP-News: Apricus Biosciences to Present Poster of Femprox(R) Phase III Clinical Data at Upcoming Industry Conference
Apricus Biosciences, Inc.
06.10.2011 15:52
—————————————————————————
SAN DIEGO, 2011-10-06 15:52 CEST (GLOBE NEWSWIRE) —
Apricus Biosciences, Inc. (–Apricus Bio– or the –Company–) (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that the submission of an abstract
entitled, –Results of a Phase III Clinical Trial for Female Sexual Arousal
Disorder (–FSAD–) with Femprox(r), a Topical Alprostadil 0.4% Cream with a Novel
Transderma
